biolitec AG
biolitec AG: biolitec AG continues on the growth path in the first half of 2011/12 by returning a group revenue of 19.36 million Euros – EBIT declines to 0.9 million Euros
biolitec AG / Key word(s): Half Year Results/Half Year Results 31.07.2012 13:53 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- biolitec AG continues on the growth path in the first half of 2011/12 by returning a group revenue of 19.36 million Euros - EBIT declines to 0.9 million Euros Jena, 31th July 2012 - biolitec AG (ISIN DE0005213409), Jena, listed on the Prime Standard of the Frankfurt Stock Exchange, achieved group sales of 19.36 million Euros in the first two quarters of the 2011/2012 fiscal year. This was 2.73 million Euros higher than that achieved in the same period in the previous fiscal year. The growth in sales is attributable to the constantly rising demand for biolitec treatments; for example, for the benign prostate hyperplasia (LIFE(TM)) and the endoluminal laser treatment for veins (ELVeS(TM)). However, even the new HeLP(TM) (Haemorrhoid Laser Procedure) treatment for the atrophy of haemorrhoidal arteries is a minimally invasive and painless treatment method that has just been successfully launched by biolitec in the market. Expenses relating to Research & Development for the first half of the 2011/2012 fiscal year for an amount of 1.86 million Euros (approximately 10% of sales) were marginally higher in percentage terms than those in the previous year (1.4 million Euros). Meanwhile, the cost of sales has increased slightly to 5.5 million Euros (compared to 5.0 million Euros in the same period of the previous year). The gross profit of 12.03 million Euros has remained at the level of the previous year (previous year: 12.05 million Euros) and the Earnings Before Interest and Tax (EBIT) declined to 0.92 million Euros (previous year: 1.2 million Euros). Significant revenues of biolitec AG were achieved in Europe and North America. The sales in North America of 7.2 million Euros were 8% higher than those in the previous fiscal year. Meanwhile, the sales in Europe reached 7.8 million Euros (previous fiscal year: 6.7 million Euros). Our subsidiaries abroad, particularly in the Middle East and in Asia, delivered sales figures that showed exceptionally high growth rates of 64% (reaching 4.4 million Euros) as compared to the first half of the previous year. Our goal in the medium-term is to increase the share of revenue in these markets to one-third of our sales and thus, to lay the foundation for further growth adapted to the new conditions in the world market. In the process, the continuous enhancement of the installed equipment base will form the basis for dynamic growth in the market for consumable items and in the pharmaceutical business. The sales figure for the Meditec segment was 18.35 million Euros in the first half of the fiscal year, while in the pharmaceuticals segment sales jumped by 60% to almost 1.0 million Euros. The earnings per share declined to 0.06 Euro compared to 0.11 Euro in the previous year. biolitec has decided to publish its results for the first two quarters of 2011/2012 even though the annual statement of accounts for 2010/2011 has not yet been audited (the unaudited sales figure for which was 35.24 million Euros). The tentative sales figures for the 2011/2012 fiscal year for the biolitec group are pegged at 40.27 million Euros. The final figures for 2010/2011 shall be published by biolitec as soon as the auditors have completed the audit of the annual accounts. In the meantime, biolitec has decided to relocate its registered office to Austria. By moving the registered office to Austria and taking into account the downstream merger in the entry standard associated with it, biolitec AG will not only be able to avail of optimising its tax liabilities such as, for example, the Austrian tax assessment for a group of companies, but it will also find itself closer to the growing markets of the future in Eastern Europe. An Extraordinary General Meeting of shareholders has been convened for this resolution on 30th August 2012. The invitation and the agenda have appeared in the 'Bundesanzeiger' (Federal Gazette) and have been published on the biolitec website. For the coming fiscal year 2012/2013, biolitec expects growth to be sustained. 31.07.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: biolitec AG Otto-Schott-Str.15 07745 Jena Germany Phone: +49 (0) 3641 519 53 0 Fax: +49 (0) 3641 519 53 33 E-mail: info@biolitec.de Internet: www.biolitec.de ISIN: DE0005213409 WKN: 521340 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden